Mar 21 |
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
|
Mar 19 |
Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market
|
Mar 18 |
Cosmos Health secures regulatory approval to sell Sky Premium Life products in UAE
|
Mar 18 |
Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders
|
Feb 29 |
Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million
|
Feb 23 |
As Trading Frenzies Grip Penny Stocks, Criticism of Nasdaq Grows
|
Feb 22 |
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
|
Feb 21 |
Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price
|
Feb 20 |
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company
|
Feb 1 |
Taglich Brothers Initiates Coverage of Cosmos Health Inc.
|